Invokana Lawsuit Numbers Gradually Increasing As Adverse Event Reports Concerning The Drug Grow As Well

March 31, 2016 – – TheProductLawyers.com reports on the details of a recent public safety communication from the U.S. Food and Drug Administration regarding type-2 diabetes, new-generation drug Invokana. The agency made this announcement on December 4th of 2015. Their message noted new requirements for Invokana’s warning label, which will be required from the drug’s manufacturer, Janssen Pharmaceuticals (a division of corporate giant Johnson & Johnson).

The concerning statement followed FDA reports that they have received many adverse event reports concerning certain potential side effects experienced by those taking the drug. These adverse event reports noted possible health problems which are reportedly appearing in patients using Invokana or various other similar SGLT2 class inhibitor drugs.

The FDA’s announcement made specific reference to a potentially life-threatening condition known as diabetic ketoacidosis. Diabetic ketoacidosis occurs when the body’s bloodstream develops excess toxic acid due to ketones. The condition can cause sufferers to enter comatose states or die, and therefore, should be taken very seriously. The FDA requested that all patients currently taking SGLT2 class inhibitor drugs be on continued lookout for symptoms that may indicate that they are developing ketoacidosis, which can include nausea and vomiting episodes, frequent urination, extreme fatigue, abdominal pain, and trouble breathing, among other things.

This is understandably concerning news, especially for type-2 diabetes patients currently using the drug. The FDA indicated that adverse event reports noted, “All patients required hospitalization or treatment in an emergency department. In many cases, ketoacidosis was not immediately recognized because the blood glucose levels were below those typically expected for diabetic ketoacidosis. As a result, treatment of the ketoacidosis was delayed in some cases.”

The attorneys of Banville Law are working to keep the public informed concerning the most recent important Invokana updates, as well as updates regarding similar drugs. To do this, they sponsor online resource website TheProductLawyers.com. In addition, they are currently helping other patients who have taken Invokana or other SGLT2-class inhibitor drugs and have suffered from medical complications that they believe were caused by the drugs. The attorneys of Banville Law wish to help ensure that affected individuals are provided with an opportunity to explore their legal rights in the matter, as they could be entitled to significant compensation attained through legal action. To better assist those looking into legal action, Banville Law is currently offering free legal consultations for qualified parties.

To request additional information, or to ask questions, contact the attorneys of Banville Law by calling 877-671-6480.

###

Contact TheProductLawyers.com:

Banville Law
877-671-6480
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009007